Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)

Brett M Stevens, PhD, Amanda Winters, MDPhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Yashaswini S Ullal, B.E, Ilu Kumari, M.Sc., Anuj Tyagi, M.Sc., Aftab Alam, M.Sc., Neelesh Lunkad, M.Tech, Leylah M. Drusbosky, PhD, Christopher R. Cogle, MD, Shireen Vali, PhD, Daniel A Pollyea, MD

Blood (2018) 132 (Supplement 1): 1538.

https://doi.org/10.1182/blood-2018-99-114429

Published: 2018

Journal Articles

Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study

Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Stephen E Kurtz, PhD, Cristina E. Tognon, PhD, Leylah M. Drusbosky, PhD, Robinson Vidva, B.Tech, Yugandhara Narvekar, M.Sc., Ashish Kumar Agrawal, B.V.Sc, A.H., Saji Gera, M.Tech, Samiksha Avinash Prasad, M.Sc., Vijayashree P Shyamasundar, M.Sc., Gaurav Singh Tunwer, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 1540.

https://doi.org/10.1182/blood-2018-99-115284

Published: 2018

Journal Articles

Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study

Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Leylah M. Drusbosky, PhD, Diwyanshu Sahu, M.Sc., Robinson Vidva, B.Tech, Shweta Kapoor, M.Sc., Humera Azam, M.Sc., Rajeev Kumar, B.Tech, Padmagiri G Chickdipatti, B.E, Nithya T Raveendaran, M.Tech, Reshma P Gopi, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2018-99-115678

Published: 2018

Journal Articles

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Chandan Kumar, M.Tech, Rakhi Purushothaman Suseela, B.Tech, Mamatha Patil, B.E, Patil Nilesh Dattatraya, M.Sc., Krishna Kumar Tiwari, B.Tech, Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 5506.

https://doi.org/10.1182/blood-2018-99-114466

Published: 2018

Journal Articles

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Andrej Besse, M.Sc, Christopher R. Cogle, MD, Leylah M. Drusbosky, PhD, Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Neha G Gupta, M.Sc., Abha Kushwaha, M.Sc., Pallavi Kumari, M.Sc., Karthik Sundara Raju, M.Sc., Ganesh Naga, B.Tech, Sayani Basu, M.Tech, Christoph Driessen, MD, Lenka Besse, PhD

Blood (2018) 132 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2018-99-116939

Published: 2018

Journal Articles

Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study

Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Shahabuddin Usmani, M.Sc., Deepak Anil Lala, B.Tech, Poornachandra G, B.Tech, Saumya Radhakrishnan, B.Tech, Shivgonda C Birajdar, MCA, Ganesh Naga, B.Tech, Leylah M. Drusbosky, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 3086.

https://doi.org/10.1182/blood-2018-99-115821

Published: 2018

Journal Articles

Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Yashaswini S Ullal, B.E, Sirisha Narayanabhatia, M.Sc., Aktar Alam, BCA, Kunal Ghosh Roy, M.Sc., Ashish Choudhary, M.Sc., Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2018-99-114610

Published: 2018

Journal Articles

Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics

Brett M. Stevens, PhD, Amanda Winters, MD PhD, Jonathan A Gutman, MD, Aaron Fullerton, BS, Gregory Hemenway, MS2, Nicholas Miltgen, BS, Qi Wei, MD, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Neeraj Kumar Singh, B.Tech, Leylah M. Drusbosky, PhD, Chris R. Cogle, MD, Andrew Hammes, MS, Craig T. Jordan, PhD, Daniel A. Pollyea, MD

Blood (2017) 130 (Supplement 1): 1337.

https://doi.org/10.1182/blood.V130.Suppl_1.1337.1337

Published: 2017

Journal Articles

Computational Modeling of Protein Networks Predicts Treatment Outcomes in Multiple Myeloma (MM)

Leylah M. Drusbosky, PhD, Hemant S. Murthy, MD, Helen L. Leather, Himanshu Grover, MS, Yugandhara Narvekar, MS, Pallavi Kumari, MS, Sirisha Narayanabhatia, MS, Priyanka Bhowmick, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Qing Zhang, PhD, Saad Z Usmani, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 592.

https://doi.org/10.1182/blood.V130.Suppl_1.592.592

Published: 2017

Journal Articles

Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Robinson Vidva, BT, Saji Gera, MT, Arko Das, MS, Krishna K Tiwari, BT, Vishwas Joseph, MS, Subrat Mohapatra, MS, Neelesh Lunkad, MT, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3907.

https://doi.org/10.1182/blood.V130.Suppl_1.3907.3907

Published: 2017

Journal Articles

Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Robinson Vidva, BT, Saji Gera, MT, Anjanasree V. Lakshminarayana, BE, Vijayashree P. Shyamasundar, MS, Ashish Kumar Agrawal, BS, Anay Talawdekar, MT, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3908.

https://doi.org/10.1182/blood.V130.Suppl_1.3908.3908

Published: 2017

Journal Articles

Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Madeleine Turcotte, MS, Paul Castillo, MD, Robinson Vidva, BT, Saji Gera, MT, Mohammed Sauban, BE, Priyanka Bhargav, BE, Punya Deep, MS, Shweta Kapoor, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3909.

https://doi.org/10.1182/blood.V130.Suppl_1.3909.3909

Published: 2017

Journal Articles

Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood (2017) 130 (Supplement 1): 3910.

https://doi.org/10.1182/blood.V130.Suppl_1.3910.3910

Published: 2017

Journal Articles

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood (2017) 130 (Supplement 1): 4277.

https://doi.org/10.1182/blood.V130.Suppl_1.4277.4277

Published: 2017

Journal Articles

Predicting Mechanisms of Ibrutinib-Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational-Based Modeling for Personalized Therapy with Clinical Validation

Leylah M. Drusbosky, PhD, Aneel Paulus, MD, Anne Quillet Mary, PhD, Loic Ysebaert, MD PhD, Ansu Kumar, MS, Neeraj Kumar Singh, B.Tech, Yashaswini Ullal, BE, Priyanka Bhargav, BE, Humera Azam, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Asher A. Chanan-Khan, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 4278.

https://doi.org/10.1182/blood.V130.Suppl_1.4278.4278

Published: 2017

Journal Articles

A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing

Blood (2017) 130 (Supplement 1): 2707.

https://doi.org/10.1182/blood.V130.Suppl_1.2707.2707

Published: 2017

Journal Articles

Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options

Leylah M. Drusbosky, PhD, Ansu Kumar, MS, Shwetha K, BE, Priyanka Bhargav, BE, Ashish Choudhary, MS, Soumyashree L, BE, Shivgonda C. Birajdar, MCA, Kunal Ghosh Roy, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Manju Sengar, MD DM, Girish Chinnaswamy, MD MRCP, Bijal D. Shah, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 2708.

https://doi.org/10.1182/blood.V130.Suppl_1.2708.2708

Published: 2017

Journal Articles

Computational Biology Approach to Predict Hypomethylating Agent (HMA) Response Using Genomic and Clinical Characteristics in Myelodsyplastic Syndromes (MDS)

Leylah M. Drusbosky, PhD, Salah-Eddin Komrokji, Najla Al Ali, M.Sc, Neeraj Kumar Singh, B.Tech, Chandan Kumar, MT, Sumanth Vasista, BE, Diwyanshu Sahu, M.Sc., Ganesh Naga, BT, Patil Dattatraya, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, David A Sallman, MD, Rami S. Komrokji, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 2954.

https://doi.org/10.1182/blood.V130.Suppl_1.2954.2954

Published: 2017

Journal Articles

Predictive Simulation Modeling in JAK2-Mutant MPNs Identified Ruxolitinib and Sorafenib As a Synergistic Drug Combination for Disease Modifying Therapy

Peter P. Sayeski, PhD, Leylah M. Drusbosky, PhD, Neeraj Kumar Singh, B.Tech, Anusha Pampana, Shahabuddin Usmani, MS, Mohammed Sauban, BE, Abha Kushwaha, Anu Ramakrishnan, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 5287.

https://doi.org/10.1182/blood.V130.Suppl_1.5287.5287

Published: 2017

Journal Articles

Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation

Madeleine Turcotte, MS, Raphael Charles Bosse, BS, MD PhD, Kimberly E. Hawkins, PhD BS, Amy Meacham, MS, Vindhya Vijay, MS, Girish Chinnaswamy, MD MRCP, Manju Sengar, MD DM, Ansu Kumar, MS, Shwetha K, BE, Anisha Kamath, BT, Anjana T. Nair, MS, Karthik S. Raju, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD, Leylah M. Drusbosky, PhD

Blood (2017) 130 (Supplement 1): 1448.

https://doi.org/10.1182/blood.V130.Suppl_1.1448.1448

Published: 2017

NARROW

WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)

Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study

Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study

Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System

Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics

Computational Modeling of Protein Networks Predicts Treatment Outcomes in Multiple Myeloma (MM)

Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study

Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study

Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study

Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Predicting Mechanisms of Ibrutinib-Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational-Based Modeling for Personalized Therapy with Clinical Validation

A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing

Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options

Computational Biology Approach to Predict Hypomethylating Agent (HMA) Response Using Genomic and Clinical Characteristics in Myelodsyplastic Syndromes (MDS)

Predictive Simulation Modeling in JAK2-Mutant MPNs Identified Ruxolitinib and Sorafenib As a Synergistic Drug Combination for Disease Modifying Therapy

Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only